Your browser doesn't support javascript.
loading
Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial.
Nawrocki, Steffan T; Olea, Julian; Villa Celi, Claudia; Dadrastoussi, Homa; Wu, Kaijin; Tsao-Wei, Denice; Colombo, Anthony; Coffey, Matt; Fernandez Hernandez, Eduardo; Chen, Xuelian; Nuovo, Gerard J; Carew, Jennifer S; Mohrbacher, Ann F; Fields, Paul; Kuhn, Peter; Siddiqi, Imran; Merchant, Akil; Kelly, Kevin R.
Afiliação
  • Nawrocki ST; Division of Hematology and Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona.
  • Olea J; Division of Hematology, Health Sciences Campus, University of Southern California, Los Angeles, California.
  • Villa Celi C; Division of Hematology, Health Sciences Campus, University of Southern California, Los Angeles, California.
  • Dadrastoussi H; Division of Hematology, Health Sciences Campus, University of Southern California, Los Angeles, California.
  • Wu K; Division of Hematology, Health Sciences Campus, University of Southern California, Los Angeles, California.
  • Tsao-Wei D; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Colombo A; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Coffey M; Oncolytics Biotech, Inc, Calgary, Alberta, Canada.
  • Fernandez Hernandez E; Division of Hematology, Health Sciences Campus, University of Southern California, Los Angeles, California.
  • Chen X; Division of Hematology, Health Sciences Campus, University of Southern California, Los Angeles, California.
  • Nuovo GJ; The Ohio State University Comprehensive Cancer Center Columbus, Columbus, Ohio.
  • Carew JS; Division of Hematology and Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona.
  • Mohrbacher AF; Division of Hematology, Health Sciences Campus, University of Southern California, Los Angeles, California.
  • Fields P; Formerly, Adaptive Biotechnologies, Seattle, Washington; currently, Tempus Labs, Seattle, Washington.
  • Kuhn P; USC Michelson Center for Convergent Biosciences and Department of Biological Sciences, University of Southern California, Los Angeles.
  • Siddiqi I; Department of Pathology, University of Southern California, Los Angeles, California.
  • Merchant A; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
  • Kelly KR; Division of Hematology, Health Sciences Campus, University of Southern California, Los Angeles, California.
Clin Cancer Res ; 29(24): 5087-5103, 2023 12 15.
Article em En | MEDLINE | ID: mdl-37812476
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Viral Oncolítica / Mieloma Múltiplo Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Viral Oncolítica / Mieloma Múltiplo Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article